详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

文献详情

资源类型：

作者：

机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences and School of Medicine of South China University of Technology, 106 Zhongshan 2nd Road, Guangzhou 510080, China

出处：

DOI：

ISSN：

关键词： PD-1 inhibitor PD-L1 inhibitor Clinical trials China

摘要：

Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunotherapy in 270 clinical studies. However, Chinese clinical trials of these agents remain in the early stages. We summarize the ongoing international and domestic clinical trials using PD-1 and PD-L1 inhibitors to treat lung cancer. This information can help researchers better understand the active and approved clinical trials in China, as well as the ongoing research regarding PD-1 and PD-L1 inhibitors.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 2 区医学

小类 | 2 区血液学 2 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区血液学 1 区肿瘤学

第一作者：

第一作者机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences and School of Medicine of South China University of Technology, 106 Zhongshan 2nd Road, Guangzhou 510080, China

通讯作者：

通讯机构： [1]Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences and School of Medicine of South China University of Technology, 106 Zhongshan 2nd Road, Guangzhou 510080, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]中国PD-1/PD-L1抑制剂治疗肺癌临床试验概况 [2]PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study [3]A PD-1 /PD-L1 proximity assay as a theranostic marker for PD-1 blockade in patients with metastatic melanoma. [4]Pretreatment pulmonary tumor necrosis is a promising prognostic imaging biomarker for first-line anti-PD-1/PD-L1 therapy in advanced lung squamous cell carcinoma: a multi-institutional, propensity score-matching cohort analysis [5]Barriers and facilitators to participation in clinical trial among lymphoma patients from Sun Yat-sen University Cancer Center in China An observation study [6]Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis [7]A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions. [8]Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma [9]Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). [10]Changes in Drug Clinical Trials of Thyroid Diseases in China, 2009-2022